Lymphomas | Clinical

FDA Considers Parsaclisib for Approval in FL, MZL, and MCL

November 01, 2021

The FDA is considering an application parsaclisib as treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, and granted priority review for 2 of the 3 indications.